i2O Therapeutics Receives Strategic Investment from Colorcon Ventures and Enters into Research Collaboration with Colorcon

Written by Shahrzad Missaghi - Director, Technical Strategy & Business Development | Dec 3, 2020 5:00:00 AM

i2O Therapeutics Receives Strategic Investment from Colorcon Ventures and Enters into Research Collaboration with Colorcon

Partnership to help accelerate development of i2O’s ionic liquid technology for oral delivery of challenging drugs

View full post